(Q44626161)

4 December 2017

title

Different dissolution media lead to different crystal structures of talinolol with impact on its dissolution and solubility (English)

1 reference

4 December 2017

1 reference

4

1 reference

4 December 2017

Daniel Wagner

1

1 reference

4 December 2017

Natalie Glube

series ordinal

2

1 reference

4 December 2017

Nicole Berntsen

series ordinal

3

1 reference

4 December 2017

Peter Langguth

series ordinal

5

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Drug Development and Industrial Pharmacy

4 December 2017

published in

1 reference

4 December 2017

volume

29

1 reference

4 December 2017

issue

8

1 reference

4 December 2017

page(s)

891-902

1 reference

Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Intestinal drug efflux: formulation and food effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Membrane transport of drugs in different regions of the intestinal tract of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDDC-120024185

21 January 2018

Identifiers

DOI

10.1081/DDC-120024185

1 reference

4 December 2017

1 reference